Literature DB >> 20545446

Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation.

Wahid Khan1, Neeraj Kumar.   

Abstract

BACKGROUND: Leishmania parasite is an obligate intracellular parasite of the mammalian host and lives inside resident macrophages of liver and spleen. A high dose of paromomycin (PM) is required for the treatment.
PURPOSE: Preparation and in vitro evaluation of PM loaded albumin microspheres (MS) (of size ≤ 5 µm) to target macrophages for treatment of visceral leishmaniasis.
METHODS: PM loaded MS were prepared by spray-drying method using albumin as a polymer matrix and stabilized using heat treatment. These MS were evaluated for product yield, encapsulation efficiency, particle size, size distribution, contact angle, drug-polymer interactions, and for in vitro drug release. Fluorescent labeling and in vitro uptake of these MS was assessed in RAW 264.7 cell line.
RESULTS: PM loaded albumin MS were prepared with a mean particle size ≈3 µm. Free albumin content and contact angle study confirmed the stabilization of these MS. Release studies showed biphasic release pattern. Interaction studies ruled out any possibility of drug-polymer interaction. Uptake study in macrophage confirmed the suitability of prepared MS for macrophage targeting.
CONCLUSION: The proposed drug-delivery system was found suitable for targeting macrophages in vitro and may serve as an optimum carrier to target macrophages where Leishmania parasite resides.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20545446     DOI: 10.3109/1061186X.2010.492524

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  7 in total

1.  Prospects of pharmaceuticals and biopharmaceuticals loaded microparticles prepared by double emulsion technique for controlled delivery.

Authors:  Tapan Kumar Giri; Chhatrapal Choudhary; Amit Alexander; Hemant Badwaik; Dulal Krishna Tripathi
Journal:  Saudi Pharm J       Date:  2012-05-26       Impact factor: 4.330

2.  Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay.

Authors:  Afshin Barazesh; Mohammad Hossein Motazedian; Naghmeh Sattarahmady; Mohammad Hossein Morowvat; Sajad Rashidi
Journal:  J Parasit Dis       Date:  2018-07-09

Review 3.  Leishmaniasis: where are we and where are we heading?

Authors:  Santanu Sasidharan; Prakash Saudagar
Journal:  Parasitol Res       Date:  2021-04-07       Impact factor: 2.289

4.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

5.  Molecular Identification of Species Caused Cutaneous Leishmaniasis in Southern Zone of Iran.

Authors:  Afshin Barazesh; Mohammad Hossein Motazedian; Moradali Fouladvand; Gholamreza Hatam; Saeed Tajbakhsh; Sepideh Ebrahimi; Danial Purkamal
Journal:  J Arthropod Borne Dis       Date:  2019-06-24       Impact factor: 1.198

6.  Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity.

Authors:  Shabi Parvez; Ganesh Yadagiri; Archana Karole; Om Prakash Singh; Anurag Verma; Shyam Sundar; Shyam Lal Mudavath
Journal:  Front Cell Infect Microbiol       Date:  2020-10-15       Impact factor: 5.293

7.  Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis.

Authors:  Shabi Parvez; Ganesh Yadagiri; Mallikarjuna Rao Gedda; Aakriti Singh; Om Prakash Singh; Anurag Verma; Shyam Sundar; Shyam Lal Mudavath
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.